Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Oxford BioDynamics shares drop as it might need funding by early 2023

Tue, 28th Jun 2022 11:09

(Alliance News) - Oxford BioDynamics PLC on Tuesday said it will need additional funding - either internal or external - by early 2023, as it posted a sharp drop in half-year revenue, sending its shares tumbling.

The Oxford, England-based biotechnology firm is focused on discovering and developing epigenetic biomarkers.

Providing an outlook, Oxford BioDynamics explained that, if a "reasonably likely 'downside scenario'" occurred, it "would need either to generate increased revenue or to obtain additional funding, by the end of the first quarter of 2023".

Shares fell 16% to 13.00 pence each in London on Tuesday morning.

"The group will need to generate increased revenue and/or additional funding during the remainder of the calendar year," said Chief Financial Officer Paul Stockdale. "As the remainder of the financial year progresses, the OBD team is therefore focused on growing orders for EpiSwitch CiRT and on generating revenue from pharma and other partners."

Pretax loss in the half-year that ended March 31 narrowed slightly to GBP3.4 million from GBP3.5 million a year ago. Revenue remained insubstantial, falling sharply to GBP85,000 from GBP250,000. Staff costs rose to GBP2.1 million from GBP1.9 million, though research & development costs fell to GBP191,000 from GBP601,000.

Chief Executive Officer Jon Burrows said: "This was another significant period for OBD. We further cemented the group's fundamentals to focus on commercialisation, culminating with the successful launch of our flagship EpiSwitch CiRT test in February 2022."

Brian White, analyst from Shore Capital Markets Ltd, cautioned: "These remain early days for such a potentially transformational change with the company’s flagship EpiSwitch CiRT only recently introduced (February 2022) to the key US market and as recently as June in the UK.

"As a result, financial performance during the period remained modest during the interim period. If successful, we expect the company to roll out additional commercial tests in future, offering the prospects of a growing franchise and operating leverage."

The EpiSwitch CiRT blood test predicts a patient's likely response to immune checkpoint inhibitor, or ICI, therapies, with high levels of sensitivity, specificity, accuracy and negative predictive value across 15 cancer indications where ICI treatments are approved. It provides an alternative to the more invasive biopsy option, and helps physicians to consider treatment options for the patient. The test has been available online since last Tuesday.

By Tom Budszus; tombudszus@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Related Shares

More News
14 Mar 2024 16:53

TRADING UPDATES: FireAngel CFO resigns; ECR Minerals raises GBP585,000

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

13 Mar 2024 20:49

EARNINGS AND TRADING: PensionBee nears profit; OptiBiotix Indian deal

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

17 Jan 2024 10:50

CORRECT: Oxford BioDynamics plunges as annual loss widens; revenue up

(Correcting headline to show loss widened, revenue rose)

17 Jan 2024 10:43

CORRECT: Oxford BioDynamics plunge as annual profit rises; revenue up

(Correcting headline to show profit and revenue rose)

17 Jan 2024 10:35

Oxford BioDynamics shares plunge as annual revenue widens; revenue up

(Alliance News) - Oxford BioDynamics PLC on Wednesday said its full-year loss narrowed, but saw its revenue jump on contracts for EpiSwitch.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.